Andere Sprachen Rocket Pharmaceuticals, Inc.

Aktien

A2JA9Q

US77313F1066

RCKT

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 20.04.2026			% 5 Tage	Veränd. 1. Jan.
3,860 ^USD	-1,28 %		+6,04 %	+9,97 %

16.04.	US-Arzneimittelbehörde FDA: Forschungsinstitut fordert mehr Transparenz bei beschleunigten Zulassungsverfahren	RE
01.04.	FDA erteilt Priority Review Voucher für die Zulassung eines Medikaments gegen seltene pädiatrische Erkrankungen - Federal Register	RE

Andere Sprachen

16.04.	US FDA's accelerated approval for drugs needs more transparency, says research firm
01.04.	Fda issuance of a priority review voucher to the sponsor of a rare pediatric disease product application- federal register website
30.03.	Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I
30.03.	RTW Biotech net asset value grows healthily in 2025; outlook positive
27.03.	Rocket Pharma shares fall despite FDA nod for childhood disorder treatment
27.03.	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investor Concerns Linger Amid Middle East Conflict
27.03.	Rocket Pharmaceuticals Receives FDA Accelerated Approval for Kresladi
27.03.	Rocket Receives FDA Approval for Genetic Immunodeficiency Treatment
27.03.	Top Premarket Gainers
27.03.	Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
27.03.	Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
27.03.	Rocket Pharmaceuticals Announces FDA Approval of KRESLADI? for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
23.03.	Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to S&P Biotechnology Select Industry Index
02.03.	Apellis Pharmaceuticals, Inc. Appoints Mikael Dolsten to Board of Directors, Effective March 1, 2026
26.02.	Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
26.02.	Rocket Pharmaceuticals: Q4 Earnings Snapshot
26.02.	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
23.02.	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
03.02.	Kyverna Therapeutics, Inc. Appoints Mayo Pujols as Chief Technology Officer, Effective February 9, 2026
05.01.	Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
09.12.	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
25.11.	Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
18.11.	Rocket Pharmaceuticals Shares Lower After JPMorgan Downgrade
06.11.	Rocket Pharmaceuticals Q3 net loss narrows
06.11.	Rocket Pharmaceuticals: Q3 Earnings Snapshot